Normal Sheep Serum (sterile) (ab7489)
Overview
-
Product name
Normal Sheep Serum (sterile) -
Host species
Sheep -
Tested applications
Suitable for: IHC-Fr, Blocking, IHC-Pmore details -
General notes
Sheep serum for blocking in antibody-based applications or use as an antibody diluent. From mixed sex mixed strain sheep. Origin: North America.
Total Protein Concentration : 90 mg/ml (by Refractometry). Sex: Mixed breed and sex.
Raised in: Sheep
Purity: Whole antiserum
Sterilization: This product was aseptically filtered through a 0.22 micron filter into clean, pre-sterilized containers. The product was tested on trypticase soy agar for 24 hours, 48 hours and 72 hours and was found to be negative for bacteria.
Properties
-
Form
Liquid -
Storage instructions
Shipped on Dry Ice. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Concentration information loading...
-
Research areas
-
Alternative names
- sheep serum
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab7489 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-Fr |
Use at an assay dependent concentration.
|
|
Blocking |
Use at an assay dependent concentration.
|
|
IHC-P |
Use at an assay dependent concentration.
|
Notes |
---|
IHC-Fr
Use at an assay dependent concentration. |
Blocking
Use at an assay dependent concentration. |
IHC-P
Use at an assay dependent concentration. |
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (2)
ab7489 has been referenced in 2 publications.
- Arnoux I et al. Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease. Elife 7:N/A (2018). PubMed: 30179155
- Draper E et al. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. PLoS One 8:e61825 (2013). Blocking . PubMed: 23650505